Estrella Immunopharma (NASDAQ:ESLA) Now Covered by Analysts at D. Boral Capital

D. Boral Capital initiated coverage on shares of Estrella Immunopharma (NASDAQ:ESLA) in a report published on Tuesday morning,Benzinga reports. The brokerage issued a buy rating and a $16.00 price objective on the stock.

Estrella Immunopharma Price Performance

ESLA stock opened at $1.41 on Tuesday. Estrella Immunopharma has a one year low of $0.63 and a one year high of $3.23. The stock has a market cap of $50.83 million, a PE ratio of -5.40 and a beta of 0.41. The firm has a 50 day simple moving average of $1.16 and a two-hundred day simple moving average of $1.10.

Institutional Investors Weigh In On Estrella Immunopharma

An institutional investor recently raised its position in Estrella Immunopharma stock. Geode Capital Management LLC boosted its position in shares of Estrella Immunopharma, Inc. (NASDAQ:ESLA) by 22.0% in the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 93,418 shares of the company’s stock after buying an additional 16,862 shares during the quarter. Geode Capital Management LLC owned approximately 0.26% of Estrella Immunopharma worth $106,000 as of its most recent filing with the Securities & Exchange Commission. 0.35% of the stock is currently owned by institutional investors.

About Estrella Immunopharma

Estrella Immunopharma, Inc, a preclinical-stage biopharmaceutical company, develops T-cell therapies for blood cancers and solid tumors in the United States. The company's lead product candidates include EB103 for the treatment of diffuse large B-cell lymphoma and is in pre clinical trial; and EB104 to treat diffuse large B-cell lymphoma and acute lymphocytic leukemia.